Table 1.
Cryoablation combined with adoptive cell immunotherapies.
| NCT ID | Title | Type of immune therapy combined with cryoablation | Phase |
|---|---|---|---|
| NCT02423928 | Phase I clinical trial of cryoimmunotherapy against prostate Cancer (CryoIT) | DC adoptive transfer + Ipilimumab | Phase I |
| NCT03325101 | Dendritic cell therapy after cryosurgery in combination with pembrolizumab in treating patients with stage iii-iv melanoma that cannot be removed by surgery | DC adoptive transfer + Pembrolizumab | Phase I/II |
| NCT03035331 | Dendritic cell therapy, cryosurgery, and pembrolizumab in treating patients with non-hodgkin lymphoma | DC adoptive transfer + Pembrolizumab | Phase I/II |
| NCT02849366 | Combination of cryosurgery and NK immunotherapy for recurrent sarcoma | NK cell adoptive transfer | Phase I/II |
| NCT02849327 | Combination of cryosurgery and NK immunotherapy for recurrent pharyngeal cancer | NK cell adoptive transfer | Phase I/II |
| NCT02843802 | Combination of cryosurgery and NK immunotherapy for advanced liver cancer | NK cell adoptive transfer | Phase I/II |
| NCT02843581 | Combination of cryosurgery and NK immunotherapy for advanced esophageal cancer | NK cell adoptive transfer | Phase I/II |
| NCT02843815 | Combination of cryosurgery and NK immunotherapy for advanced non-small cell lung cancer | NK cell adoptive transfer | Phase I/II |
| NCT02844335 | Combination of cryosurgery and NK immunotherapy for advanced breast cancer | NK cell adoptive transfer | Phase I/II |
| NCT02849353 | Combination of cryosurgery and NK immunotherapy for recurrent ovarian cancer | NK cell adoptive transfer | Phase I/II |
| NCT02849314 | Combination of cryosurgery and NK immunotherapy for recurrent laryngeal cancer | NK cell adoptive transfer | Phase I/II |
| NCT02849379 | Combination of cryosurgery and NK immunotherapy for recurrent tongue cancer | NK cell adoptive transfer | Phase I/II |
| NCT02849340 | Combination of cryosurgery and NK immunotherapy for recurrent cervical cancer | NK cell adoptive transfer | Phase I/II |
| NCT02843607 | Combination of cryosurgery and NK immunotherapy for advanced kidney cancer | NK cell adoptive transfer | Phase I/II |
| NCT03501056 | Study of activated cytokine-induced killer armed with bispecific antibody for advanced lung cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03484962 | Study of activated cytokine-induced killer armed with bispecific antibody for advanced liver cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03509298 | Study of activated cytokine induced killer armed with bispecific antibody for advanced pancreatic cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03540199 | Study of activated cytokine-induced killer armed with bispecific antibody for advanced kidney cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03524274 | Study of activated cytokine-induced killer armed with bispecific antibody for advanced colorectal cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03554395 | Study of activated cytokine-induced killer armed with bispecific antibody for advanced gastric cancer | CIK cell adoptive transfer + CD3-MUC-1 bispecific antibody | Phase II |
| NCT03183219 | Safety and efficiency of γδ T cell against liver cancer | γδ T cell adoptive transfer | Phase I/II |
| NCT03183232 | Safety and efficiency of γδ T cell against lung cancer | γδ T cell adoptive transfer | Phase I/II |
| NCT03180437 | Safety and efficiency of γδ T cell against pancreatic cancer | γδ T cell adoptive transfer | Phase I/II |
| NCT03183206 | Safety and efficiency of γδ T cell against breast cancer | γδ T cell adoptive transfer | Phase I/II |
| NCT02380443 | Increased frequency of allostim® immunotherapy dosing in combination with cryoablation in metastatic colorectal cancer | Adoptive transfer of activated allogenic Th1 memory cells expressing high levels of type 1 inflammatory cytokines, immunomodulatory molecules, and coated with CD3/CD28 microbeads | Phase II |
| NCT01741038 | AlloStim® in-situ vaccine in pre-treated metastatic colorectal cancer | Adoptive transfer of activated allogenic Th1 memory cells expressing high levels of type 1 inflammatory cytokines, immunomodulatory molecules, and coated with CD3/CD28 microbeads | Phase II/III |